Phaseline

Companies › C Ray Therapeutics

C Ray Therapeutics: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Ophthalmology, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RTx-015
Gene therapy delivering an optogenetic gene to retinal cells to produce light-responsive p
–Phase 2Retinitis Pigmentosa (RP); Retinitis PigmentosaOct 2028
TRDC002
PSMA-targeting radiotracer (64Cu-labeled)
PSMAPhase 1Prostate CancerDec 2026
TRC003
225Ac-labeled PSMA-targeted alpha particle therapy (targeted alpha therapy)
PSMAPhase 1Prostate CancerDec 2027
RTx-021
Optogenetic gene therapy
–Phase 1Stargardt DiseaseDec 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07236112TRDC002Phase 1Prostate CancerOncologyDec 2026
NCT07567521TRC003Phase 1Prostate CancerOncologyDec 2027
NCT07901751RTx-015Phase 2Retinitis Pigmentosa (RP)OphthalmologyOct 2028
NCT06460844RTx-015Phase 1Retinitis PigmentosaOphthalmologyOct 2030
NCT07439887RTx-021Phase 1Stargardt DiseaseOphthalmologyDec 2030

Targets

PSMA (2)

Companies with the same targets

Clarity Pharmaceuticals Nova Therapeutics Eli Lilly Fusion Pharmaceuticals Lantheus Medical Imaging Sinotau Pharmaceutical Group Norroy Bioscience Inovio Pharmaceuticals Curium US Beijing Biotech

Companies built like this

Norroy Bioscience Lantheus Medical Imaging POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company Clarity Pharmaceuticals Fusion Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.